Patients with unresectable stage III non-small cell lung cancer eligible to receive consolidation therapy with durvalumab in clinical practice based on PACIFIC study criteria
ConclusionIn clinical practice, approximately 70% of patients with unresectable stage III NSCLC would be eligible to receive consolidation therapy with durvalumab.
Source: Respiratory Investigation - Category: Respiratory Medicine Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Lung Cancer | Men | Non-Small Cell Lung Cancer | Respiratory Medicine | Study